Organization
John Mascarenhas
4 clinical trials
Clinical trial
A Phase II Open-label Study of Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationStatus: Completed, Estimated PCD: 2023-05-30
Clinical trial
A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With MyelofibrosisStatus: Completed, Estimated PCD: 2018-05-18
Clinical trial
Phase I Study of AVID200 in Patients With Myelofibrosis (Myeloproliferative Neoplasms Research Consortium [MPN-RC] 118)Status: Completed, Estimated PCD: 2022-05-16